Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

This review discusses the use of antiandrogens for various conditions like prostate cancer and highlights their potential benefits in remission rates and symptom improvement, but it reports no new clinical results.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

This review discusses the use of antiandrogen therapy in dermatology, covering treatments for conditions like acne, hirsutism, and androgenic alopecia but reports no new clinical findings.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.

This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.

This study identified pantolactam based compounds as effective topical antagonists of the androgen receptor, reducing sebum components in a hamster model.

This study reports a novel method for synthesizing substituted hydantoins, including the anticonvulsant drug ethotoin, using safer reagents and fewer steps compared to conventional protocols.

This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found that combining Flutamide and an LHRH agonist in adult male rats effectively inhibited prostatic growth and reduced androgen-sensitive prostatic activity markers to levels similar to castrated rats.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.